Mylan
Mylan N.V., a global leader in the pharmaceutical industry, is headquartered in India (IN) and operates extensively across North America, Europe, and Asia. Founded in 1961, Mylan has established itself as a key player in generic and specialty medications, focusing on improving access to high-quality healthcare solutions. The company offers a diverse portfolio of products, including generic drugs, over-the-counter medications, and complex generics, which are distinguished by their affordability and reliability. Mylan's commitment to innovation and quality has positioned it as a trusted name in the market, achieving significant milestones such as the launch of the first generic version of EpiPen. With a strong market presence and a dedication to patient-centric solutions, Mylan continues to enhance its reputation as a pioneer in the pharmaceutical sector.
DitchCarbon Score
How does Mylan's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mylan's score of 0 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mylan's reported carbon emissions
In 2022, Mylan reported total carbon emissions of approximately 3,000,000,000 kg CO2e, comprising 1,793,470,000 kg CO2e from Scope 1, 434,568,000 kg CO2e from Scope 2, and 1,380,972,000 kg CO2e from Scope 3 emissions. This data highlights the company's significant carbon footprint, particularly in Scope 3, which includes emissions from the supply chain and product use. Over the years, Mylan's emissions have fluctuated, with total emissions recorded at 653,000,000 kg CO2e in 2015, increasing to 661,000,000 kg CO2e in 2016, and peaking at 676,000,000 kg CO2e in 2018. The company has not disclosed specific reduction targets or initiatives aimed at decreasing its carbon emissions, indicating a potential area for improvement in its climate commitments. Mylan's emissions data reflects the broader pharmaceutical industry's challenges in managing carbon footprints, particularly in Scope 3 emissions, which often represent the largest share of total emissions. As the company continues to navigate its environmental impact, establishing clear reduction targets and strategies will be crucial for aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2015 | 2016 | 2017 | 2018 | 2019 | 2022 | |
|---|---|---|---|---|---|---|
| Scope 1 | 299,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
| Scope 2 | 354,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mylan is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
